Jorenby D - Search Results

1

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

Chen LS, Baker TB, Jorenby D, Piper M, Saccone N, Johnson E, Breslau N, Hatsukami D, Carney RM, Bierut LJ. Chen LS, et al. Among authors: jorenby d. Drug Alcohol Depend. 2015 Sep 1;154:278-82. doi: 10.1016/j.drugalcdep.2015.06.022. Epub 2015 Jun 23. Drug Alcohol Depend. 2015. PMID: 26142345 Free PMC article. Clinical Trial.

2

Predicting relapse back to smoking: contrasting affective and physical models of dependence.

Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB. Kenford SL, et al. J Consult Clin Psychol. 2002 Feb;70(1):216-27. J Consult Clin Psychol. 2002. PMID: 11860048

3

Impact of prior nicotine replacement therapy on smoking cessation efficacy.

Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, Nides MA, Ascher JA, Johnston JA. Durcan MJ, et al. Am J Health Behav. 2002 May-Jun;26(3):213-20. doi: 10.5993/ajhb.26.3.6. Am J Health Behav. 2002. PMID: 12018757 Clinical Trial.

4

Clinical efficacy of bupropion in the management of smoking cessation.

Jorenby D. Jorenby D. Drugs. 2002;62 Suppl 2:25-35. doi: 10.2165/00003495-200262002-00003. Drugs. 2002. PMID: 12109933 Review.

5

Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers.

Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Piasecki TM, et al. J Abnorm Psychol. 2003 Feb;112(1):3-13. J Abnorm Psychol. 2003. PMID: 12653409 Clinical Trial.

6

Smoking withdrawal dynamics: II. Improved tests of withdrawal-relapse relations.

Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Piasecki TM, et al. J Abnorm Psychol. 2003 Feb;112(1):14-27. J Abnorm Psychol. 2003. PMID: 12653410 Clinical Trial.

7

Targeting smokers at increased risk for relapse: treating women and those with a history of depression.

Smith SS, Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Jamerson B, Fiore MC, Baker TB. Smith SS, et al. Nicotine Tob Res. 2003 Feb;5(1):99-109. doi: 10.1080/1462220021000060437. Nicotine Tob Res. 2003. PMID: 12745511 Clinical Trial.

8

Use of the vital sign stamp as a systematic screening tool to promote smoking cessation.

Piper ME, Fiore MC, Smith SS, Jorenby DE, Wilson JR, Zehner ME, Baker TB. Piper ME, et al. Mayo Clin Proc. 2003 Jun;78(6):716-22. doi: 10.4065/78.6.716. Mayo Clin Proc. 2003. PMID: 12934781 Clinical Trial.

9

Smoking withdrawal dynamics: III. Correlates of withdrawal heterogeneity.

Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Piasecki TM, et al. Exp Clin Psychopharmacol. 2003 Nov;11(4):276-85. doi: 10.1037/1064-1297.11.4.276. Exp Clin Psychopharmacol. 2003. PMID: 14599261 Clinical Trial.

Five parameters of postcessation smoking withdrawal variability derived from clinical data (T. M. Piasecki, D. E. Jorenby, S. S. Smith, M. C. Fiore, & T. B. Baker, 2003a, 2003b) were predicted from baseline measures and pharmacotherapy assignment. ...

Five parameters of postcessation smoking withdrawal variability derived from clinical data (T. M. Piasecki, D. E. Jorenby, S. …

10

Integrating smoking cessation treatment into primary care: an effectiveness study.

Fiore MC, McCarthy DE, Jackson TC, Zehner ME, Jorenby DE, Mielke M, Smith SS, Guiliani TA, Baker TB. Fiore MC, et al. Prev Med. 2004 Apr;38(4):412-20. doi: 10.1016/j.ypmed.2003.11.002. Prev Med. 2004. PMID: 15020174 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

111 results

Search Page

Filters